Valink Therapeutics Raises $11.8 Million to Advance Bispecific ADC Platform for Cancer Treatment
核心洞察
Valink Therapeutics (搜索) closed an $11.8 million pre-A funding round led by redalpine (搜索) to advance its next-generation bispecific antibody-drug conjugate (bsADC) platform for oncology applications.
The company's proprietary V-gate technology aims to overcome limitations of traditional ADCs by combining innovative targeting strategies with more precise payload delivery to enhance therapeutic efficacy and safety.
Funding will accelerate development of Valink's first-in-class cancer therapeutics toward key preclinical milestones and support expansion into the U.S. market with new headquarters in Cambridge, Massachusetts.
Valink Therapeutics (搜索) has successfully closed an $11.8 million pre-A funding round to advance its pipeline of next-generation bispecific antibody-drug conjugates (bsADCs) designed to improve outcomes for cancer patients. The financing was led by European venture capital fund redalpine (搜索), with participation from new investors LongeVC (搜索) and Oxford Science Enterprises (搜索), alongside continued support from existing investors RV Invest (搜索), p53 Invest (搜索), and Hoxton Ventures (搜索).
The biotechnology company will use the proceeds to accelerate development of its first-in-class cancer therapeutics toward key preclinical milestones and support its expansion into the United States, where it has established headquarters in Cambridge, Massachusetts.
Addressing ADC Limitations Through Bispecific Design
Valink's bsADC platform is designed to overcome critical limitations of traditional antibody-drug conjugates by combining innovative targeting strategies with more precise and efficient payload delivery. The company's proprietary V-gate framework represents what it describes as a new paradigm in antibody-drug conjugate design, allowing for fine-tuned control over target selection and synergistic biological effects.
"Our V-gate approach and proprietary drug discovery engine expand the frontier of antibody drug conjugates, offering the potential for first-in-class medicines to address areas of high unmet need in oncology and beyond," said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink Therapeutics (搜索).
The V-gate technology enables the generation of therapeutics that can address complex disease mechanisms with greater precision, potentially expanding the therapeutic index of ADC-based treatments. This flexibility allows Valink to develop treatments for multiple cancer types, including solid tumors such as colorectal cancer.
Expanding Beyond Traditional ADCs
Beyond bispecific ADCs, Valink is exploring multispecific ADCs, multifunctional agonists, and protein-based therapeutic platforms that broaden its ability to treat various cancer indications. The company has developed proprietary protein technologies for multispecific or multifunctional ADCs and multivalent agonists.
Valink is currently advancing two oncology programs into preclinical development for solid tumor indications, including colorectal cancer. The company's approach aims to enhance both therapeutic efficacy and safety, ultimately improving outcomes for patients with cancer and other serious diseases.
Investor Confidence in Novel Platform
Michael Sidler, redalpine (搜索) founding partner and member of Valink Therapeutics (搜索) board of directors, emphasized the significance of the company's technological approach. "Valink's discovery platform and V-gate approach represent a compelling advancement on traditional ADC strategies - unlocking new therapeutic possibilities by fusing programmable biology and a novel framework for target synergy," Sidler said.
The investment reflects confidence in Valink's ability to address real-world disease biology with precision and adaptability. Redalpine (搜索) has previously backed notable ADC companies, including Araris Biotech (搜索), which was recently acquired by Taiho (搜索).
Transatlantic Expansion Strategy
With the new funding, Valink is positioned to advance its oncology programs and establish itself as a leader in bispecific and multispecific drug conjugate innovation. The company maintains a research and development subsidiary (Valink Therapeutics (搜索) Ltd) and facilities in the United Kingdom, while expanding its presence in the U.S. market.
The company's expansion into Cambridge underscores its commitment to bridging European and U.S. scientific ecosystems to accelerate breakthrough cancer therapies. This transatlantic presence, combined with strong investor backing, positions Valink to advance its innovative ADC platform toward clinical development.